Form 4: BioXcel CFO Acquires Shares via RSU Vesting

BioXcel Therapeutics' CFO, Richard Steinhart, acquired additional common stock through the routine vesting of Restricted Stock Units.

Summary

• Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership.
• On September 14, 2025, Mr. Steinhart acquired 33 shares of Common Stock upon the vesting of Restricted Stock Units (RSUs).
• Following this transaction, his direct beneficial ownership of Common Stock was 6,474 shares.
• On September 15, 2025, Mr. Steinhart acquired an additional 35 shares of Common Stock from RSU vesting.
• After the September 15, 2025 transaction, his direct beneficial ownership of Common Stock increased to 6,509 shares.
• The RSUs represent a contingent right to receive one share of the Issuer's Common Stock, with an exercise price of $0.
• A grant of 521 RSUs occurred on March 14, 2022, vesting 25% on the first anniversary and 6.25% quarterly thereafter.
• A grant of 562 RSUs occurred on March 15, 2023, vesting 25% on the first anniversary and 6.25% quarterly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects routine insider share acquisition through vesting, indicating continued alignment of management with shareholder interests, without any negative implications.

Positives

• Increased insider ownership, even through routine vesting, can signal management's continued alignment with shareholder interests.
• The transactions are part of a pre-scheduled equity compensation plan, indicating stability in executive compensation.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive may be viewed positively, suggesting continued commitment and alignment with long-term company performance.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to the established schedules (6.25% of total RSUs at the end of each successive three-month period).

Key Dates

Recommendation

This Form 4 reports routine, pre-scheduled vesting of Restricted Stock Units for the CFO, leading to a minor increase in his direct beneficial ownership. Such transactions are typical for executive compensation and do not provide new fundamental information that would warrant a change in investment recommendation. The filing confirms ongoing insider alignment but does not indicate any significant shift in the company's operational or financial outlook.

Keywords

BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Common Stock, Equity Compensation